PUBLISHED ON: December 24, 2012 | Duration: 5 min, 24 sec
In conversation with NDTV, Abhaya Kumar, CEO & MD, Shasun Pharma, clarifies that the company has not recieved any warning letter from the USFDA. The company is on the path of achieving its set profit targets and has around eight APIs in the pipeline.
